ContraFect Announces Fourth Quarter and Full Year 2015 Results
15 mars 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 15, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Corporation to Announce Fourth Quarter and Full Year 2015 Results on March 15, 2016
08 mars 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 08, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a clinical-stage biotechnology company focused on the discovery and...
ContraFect to Present at 18th Annual BIO CEO and Investor Conference
02 févr. 2016 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - February 02, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a biotechnology company focused on the discovery and...
(UPDATED) UNITY Consortium Established to Support Immunizations for Today's Teens and Young Adults
28 août 2015 14h04 HE
|
UNITY Consortium
NEWTOWN, Pa., Aug. 28, 2015 (GLOBE NEWSWIRE) -- UNITY Consortium has launched as a coalition that brings together a wide range of organizations with a singular focus on improving adolescent and young...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
07 avr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
Get Added Protection Against H3N2 with A.Vogel's Clinically Proven Echinaforce(R)
03 févr. 2015 10h01 HE
|
Bioforce Canada
MONTREAL, Feb. 3, 2015 (GLOBE NEWSWIRE) -- A recent study confirms that the 2014-2015 flu vaccine offers little or no protection from this year's predominant influenza strain H3N2.
The research,...
Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
22 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans
15 sept. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
28 janv. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
07 janv. 2014 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...